PUBLISHER: The Business Research Company | PRODUCT CODE: 1948231
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948231
Smart pills are designed for the purpose of administering medication and are equipped with electronic sensors that emit signals detectable by patches or smartphones upon ingestion. These innovative pills play a crucial role in ensuring patients' adherence to their prescribed drug regimens and enable the monitoring of medication compliance.
The primary applications of smart pills encompass capsule endoscopy, patient monitoring, and drug delivery. Patient monitoring involves the repeated or continuous tracking of various patient parameters. Smart pills are used to target specific areas within the gastrointestinal tract, including the esophagus, stomach, small intestine, and large intestine, for the treatment of conditions such as esophageal diseases, colon diseases, small bowel diseases, among others. These smart pills find utility in a variety of healthcare settings, including hospitals, diagnostic centers, and research institutes.
Tariffs are influencing the smart pills market by increasing costs of imported microelectronics, sensors, transmitters, and pharmaceutical-grade materials used in ingestible devices. Healthcare providers and research institutions in North America and Europe are most affected due to reliance on imported electronic components, while Asia-Pacific faces cost pressure on device manufacturing and exports. These tariffs are raising development and production costs and slowing commercialization timelines. However, they are also encouraging localized electronics manufacturing, domestic R&D investments, and regional partnerships to advance smart pill innovation.
The smart pills market research report is one of a series of new reports from The Business Research Company that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The smart pills market size has grown rapidly in recent years. It will grow from $6.11 billion in 2025 to $6.75 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising need for patient compliance monitoring, expansion of digital health initiatives, availability of advanced ingestible sensors, growing clinical research adoption.
The smart pills market size is expected to see rapid growth in the next few years. It will grow to $10.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing demand for personalized medicine solutions, rising investments in digital therapeutics, expansion of remote patient monitoring, growing adoption of smart drug delivery platforms, increasing regulatory support for connected health technologies. Major trends in the forecast period include increasing adoption of sensor-enabled drug delivery systems, rising focus on medication adherence solutions, growing integration with mobile health platforms, expansion of smart ingestible diagnostics, enhanced development of miniaturized electronics.
The increasing preference for non-invasive procedures is anticipated to drive the growth of the smart pills market in the coming years. Non-invasive procedures do not involve incisions or tissue removal, thereby reducing patient risk and shortening recovery time. The growing preference for non-invasive approaches is attributed to their ability to deliver effective diagnostic and therapeutic outcomes while minimizing physical burden on patients. Smart pills support non-invasive procedures by enabling internal imaging and physiological monitoring without the need for surgical entry, allowing clinicians to collect diagnostic information through a simple swallowable device. For example, in March 2024, according to NHS England, a UK-based public health service, more than 5,400 patients benefited from colon capsule endoscopy pill-cam pilot programs across 53 sites. Therefore, the rising preference for non-invasive procedures is contributing to the expansion of the smart pills market.
The increasing healthcare expenditure is anticipated to drive the growth of the smart pills market in the coming years. Healthcare expenditure refers to the overall spending on medical services, treatments, infrastructure, research, and public health programs aimed at maintaining or improving health outcomes. The rising demand for healthcare expenditure is attributed to the growing prevalence of chronic mental health conditions, which necessitate ongoing treatment, medication, and long-term care support. Healthcare expenditure facilitates the advancement of smart pills by financing innovative technologies that improve drug delivery, monitoring capabilities, and patient adherence. For example, in December 2024, according to the Centers for Medicare and Medicaid Services (CMS), a US-based federal agency, national health expenditures (NHE) increased by 7.5% to reach $4.9 trillion in 2023, representing 17.6% of gross domestic product (GDP). Furthermore, from 2023 to 2032, average national health expenditures (NHE) are expected to grow at an annual rate of 5.6%, leading to an increase in the healthcare spending share of GDP from 17.3% in 2022 to 19.7% in 2032. Thus, the rising healthcare expenditure is fueling the growth of the smart pills market.
Major companies operating in the smart pills market are concentrating on the development of smart pills with customizable programs, including ingestible multi-sensor prototypes that support tailored drug delivery and in-vivo monitoring to improve treatment adherence and therapeutic outcomes. Customizable programs refer to firmware- or software-based control of sensing functions, data collection, and triggerable actions that clinicians or trial managers can configure for individual patients. For example, in 2025, the Interuniversity Microelectronics Centre, a Belgium-based research and innovation institute, introduced a prototype ingestible sensor for gut health monitoring that integrates multiple sensing modalities chemical, mechanical, and electrical along with onboard signal processing, power management, and real-time data transmission for remote monitoring. The prototype focuses on miniaturization and full-system integration to enable configurable sensing programs for personalized clinical applications.
Major companies operating in the smart pills market are Medtronic plc, Olympus Corporation, CapsoVision Inc., Novartis AG, Proteus Digital Health Inc., Koninklijke Philips N.V., MicroCHIPS Inc., Bio-Images Drug Delivery (BDD) Ltd., Given Imaging Ltd., Vitality Inc., Boston Scientific Corporation, HQ Inc., Fujifilm Holdings Corporation, General Electric Company, Check-Cap Ltd., IntroMedic Co. Ltd., Jinshan Science & Technology Co. Ltd., PENTAX Medical, etectRx Inc., Pixie Scientific HQ Inc., ANX Robotica Corp., RF Co. Ltd., Shenzhen Jifu Medical Technology Co. Ltd., Otsuka America Pharmaceutical Inc., Medimetrics Personalized Drug Delivery B.V., Smart Pill Inc., Medisafe Inc., AdhereTech LLC, TabSafe Medical Services Inc.
North America was the largest region in the smart pills market in 2025. Western Europe was the second-largest region in the smart pills market analysis. The regions covered in the smart pills market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the smart pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Smart Pills Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses smart pills market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for smart pills ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The smart pills market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.